The following subsections help patients and their families understand different treatment strategies with bispecific antibody therapy. 

  Are bispecific antibody therapies being combined with other anti-myeloma therapies?

  Are bispecific therapies being combined with each other to treat multiple myeloma?

  What is the proper sequencing of immunotherapies to treat myeloma?

  How can BCMA-directed therapies be sequenced to treat myeloma?

  Can bispecific antibodies be used to treat newly diagnosed patients?

  If one bispecific antibody stops working, can I be prescribed a different bispecific?

  What if my myeloma doesn’t respond to bispecific antibodies?